Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab with Taxane/Trastuzumab/Pertuzumab in First-Line HER2-Positive Metastatic Breast Cancer
NCT03199885Phase 3Terminated
- Sponsor
- National Cancer Institute
- Start
- Apr 2019
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of atezolizumab in HER2-positive metastatic breast cancer, sponsored by National Cancer Institute. Started Apr 2019; status: terminated.
02
Drugs
atezolizumab
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT03199885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03199885.